Critical evaluation Merck

• Faced with problematic growth, merck is expected to pursue strategic options including operational cost efficiencies, M&A with other Big Pharma companies, biotech, Mid Pharma players and/or generics manufacturers and acquisitional moves outside of 'pharma space' to increase presence in medical devices, diagnostics and consumer healthcare.

• Product must be launched and carried in the market with utmost care to avoid self controversial situations like that in the case of vioxx, which could be responsible for various disorders and health related issues.

• The regulatory bodies should be provided the drug samples after proper in house checking of the drug effect on the body, as its absence invites more lag in future approval of the further drugs.

• Extension of the product patent duration should be sought, as much as possible